Kodiak Sciences' Second Phase 3 Win Makes Its Eye Drug Ready for FDA Submission

The data

GLOW2 was designed to replicate and extend GLOW1's findings, and it did so across every prespecified endpoint. The study expanded the patient population to include those with proliferative diabetic retinopathy (PDR) and mild diabetic macular edema (DME), a higher-risk group than GLOW1 enrolled.

The key secondary endpoints were equally strong. Zenkuda demonstrated an 85 percent risk reduction in the development of sight-threatening complications (2.4 percent with Zenkuda versus 15.8 percent with sham, p=0.0001), and 13.7 percent of Zenkuda patients achieved a three-step or greater DRSS improvement versus zero percent with sham (p<0.0001). In GLOW1, the risk reduction for sight-threatening complications was 89 percent: the consistency across the two studies is notable.

Perhaps the most commercially relevant finding: Zenkuda's efficacy was independent of concomitant GLP-1 receptor agonist use. Among Zenkuda-treated patients using GLP-1 medications (46.1 percent of the treatment arm), 60.0 percent achieved the primary endpoint, compared with 64.3 percent among those not using GLP-1 drugs. That matters because the explosive growth of GLP-1 agonists for diabetes and obesity has raised questions about whether improved metabolic control might reduce the addressable market for diabetic retinopathy therapies. GLOW2 was the first registration trial in the indication to place no restrictions on GLP-1 use, and the data suggest Zenkuda's benefit is additive.

Safety and durability

The safety profile was clean. Kodiak reported zero cases of intraocular inflammation in the study, and no cases of retinal vasculitis or occlusive retinal vasculitis. The cataract adverse event rate was 2.3 percent with Zenkuda versus 1.6 percent with sham, in line with expected background rates for diabetic retinopathy patients.

The durability story is central to Zenkuda's commercial thesis. All patients in GLOW2 reached six-month dosing intervals by the end of the study (with injections at baseline, Week 4, Week 8, Week 20, and Week 44). Existing anti-VEGF therapies for diabetic retinopathy typically require injections every four to eight weeks. A six-month dosing interval, if approved, would represent a meaningful reduction in treatment burden for patients and providers.

The broader pipeline

Zenkuda's GLOW2 readout is the headline, but it arrives in the context of a pipeline that has generated sustained momentum across multiple programs. Kodiak's third-quarter 2025 business update outlined several upcoming catalysts: the Phase 3 DAYBREAK study of tarcocimab and KSI-501 in wet age-related macular degeneration (AMD), with topline data expected in the third quarter of 2026; the Phase 3 PEAK study of KSI-101 in macular edema secondary to inflammation (MESI), with topline data expected in the fourth quarter of 2026; and the Phase 3 PINNACLE study of KSI-101, with data expected in the first quarter of 2027.

To be sure, Kodiak remains a precommercial company burning significant cash. The company reported a net loss of $61.5 million in the third quarter of 2025 (up from $43.9 million a year earlier), driven by increased clinical activity across its Phase 3 programs. Cash and cash equivalents stood at $72.0 million at the end of September 2025. Kodiak subsequently priced an upsized $160 million stock offering at $23.00 per share, which provides a longer runway but also dilutes existing shareholders.

The valuation question

At $35.91, Kodiak's market capitalization sits at approximately $1.9 billion. The stock has gained 38 percent year to date, dramatically outperforming the broader market (the S&P 500 is down 0.4 percent over the same period). But the analyst consensus suggests further upside: 11 of 18 analysts covering the stock rate it a Buy, with a median price target of $44 and a high target of $50.

The bull case is straightforward: Zenkuda now has two confirmatory Phase 3 wins in diabetic retinopathy, a clean safety profile, a differentiated six-month dosing interval, and a clear path to BLA submission. The addressable market is large (diabetic retinopathy affects an estimated 9.6 million Americans), and the treatment burden of existing therapies has limited their uptake in earlier-stage disease. If Zenkuda can shift the standard of care toward less frequent dosing, the commercial opportunity is substantial.

But the risks are real. Kodiak has no approved products and no revenue. The BLA filing timeline has been described as "accelerated" but not specified. The DAYBREAK study in wet AMD, a larger and more competitive market, has yet to read out. And the company's cash position, even after the recent offering, will need to fund not only regulatory submissions but also the buildout of a commercial infrastructure from scratch.

The GLOW2 data remove one of the largest binary risks from Kodiak's story. The question now is execution: whether the company can translate two strong Phase 3 datasets into an FDA approval, a commercial launch, and ultimately revenue. Only time will tell, but the clinical evidence is no longer in doubt.